Ninlib 200mg Capsule
Rx RequiredSalt Composition: Nilotinib
Expiry Date: 01/2028
Price on Request
Inclusive of all taxes
30 capsule in Bottle
About The Product
Blood Cancer
Ninlib 200mg Capsule is an anticancer medicine with Nilotinib (200mg) as an active ingredient. It is prescribed to treat chronic myeloid leukaemia a type of blood cancer.
It works by blocking the action of specific proteins to slow down the growth of cancer cells and progression of disease.
It can be used alone or in combination with other medicines. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.
Uses
Blood cancer (Chronic myeloid leukaemia)
Side Effects
Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.
Some common side effects of Ninlib 200mg Capsule include:
- Fatigue
- Headache
- Nausea
- Muscle pain
- Abdominal pain
- Rash
- Itching
- Hair loss
Contact your healthcare provider if you face any unusual or persistent side effects.
How To Use
- The dosage and duration of the Ninlib 200mg Capsule are decided by the doctor based on the severity of the cancer and other health factors.
- Take this tablet on an empty stomach for better results.
- Before starting this medicine, please inform your doctor about your medical history.
- If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.
How It Works
Ninlib 200mg Capsule contain active ingredient Nilotinib. It is a targeted therapy based anticancer drug that works by blocking the action of proteins (kinases) which are responsible for the growth and division of cells.
Results in slows the growth of cancer cells and eventually kills them.
Safety Advice
Avoid the consumption of alcohol while taking Ninlib 200mg Capsule, as alcohol can decrease the effectiveness of the medicine as well as worsen the symptoms.
Do not take Ninlib 200mg Capsule without consulting the doctor in case of pregnancy, as it can be unsafe to take it during this period.
Breastfeeding women should discuss the potential risks and benefits of the Ninlib 200mg Capsule with their healthcare provider before starting treatment.
Ninlib 200mg Capsule may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving.
Share your medical history with the doctor before starting the Ninlib 200mg Capsule. Do not take it without consulting a doctor if you have any kidney related issue.
Share your medical history with the doctor before starting the Ninlib 200mg Capsule. Do not take it without consulting a doctor if you have any liver related issue.
FAQs
It is used in the treatment of chronic myeloid leukaemia a type of blood cancer.
It belongs to a group of cancer-fighting medications known as antineoplastics.
References
- DeRemer, D. L., Ustun, C., & Natarajan, K. (2008). Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clinical therapeutics, 30(11), 1956-1975.
- Le Coutre, P., Rea, D., Abruzzese, E., Dombret, H., Trawinska, M. M., Herndlhofer, S., ... & Valent, P. (2011). Severe peripheral arterial disease during nilotinib therapy. Journal of the National Cancer Institute, 103(17), 1347-1348.
- Quintás-Cardama, A., Kantarjian, H., & Cortes, J. (2012). Nilotinib-associated vascular events. Clinical Lymphoma Myeloma and Leukemia, 12(5), 337-340.
- Ostendorf, B. N., le Coutre, P., Kim, T. D., & Quintás-Cardama, A. (2014). Nilotinib. Small Molecules in Oncology, 67-80.
- Saglio, G., Kim, D. W., Issaragrisil, S., Le Coutre, P., Etienne, G., Lobo, C., ... & Kantarjian, H. M. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362(24), 2251-2259.
- Blay, J. Y., & von Mehren, M. (2011, April). Nilotinib: a novel, selective tyrosine kinase inhibitor. In Seminars in oncology (Vol. 38, pp. S3-S9). WB Saunders.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
